Jennifer Hibma

8PUBLICATIONS
23CO-AUTHORS
PharmacogenomicsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Neurology and neuromuscular diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 13, 2026
Elranatamab Population Pharmacokinetics and Exposure-Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma.

|Jun 13, 2026
AI-Powered Lesion-Level Tumor Growth Inhibition Modeling Improves Model Stability and Prognostic Association With PFS.

|Mar 12, 2026
Population Pharmacokinetic Modeling of Encorafenib in Healthy Participants and Patients with BRAF V600-Mutant Solid Tumors: A Semi-mechanistic Autoinduction Model.

Derek Z Yang, Erik M Hahn, Joseph Piscitelli

|Feb 27, 2024
Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma.

Ping Hu, Haiqing Isaac Dai, James Bourdage

|Jan 31, 2023
Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy.

Jennifer E Hibma, Priya Jayachandran, Srividya Neelakantan

|Mar 18, 2022
Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.

Jennifer E Hibma, Melissa O'Gorman, Sunil Nepal

Pageof 2

Frequent Collaborators

2 joint publications

Yazdi K Pithavala

1 joint publications

Priya Jayachandran

1 joint publications

Lutz O Harnisch

1 joint publications

Derek Z Yang